Stem definition | Drug id | CAS RN |
---|---|---|
heparin derivatives including low molecular mass heparins | 4840 | 9041-08-1 |
Molecule | Description |
---|---|
Synonyms:
|
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
|
Dose | Unit | Route |
---|---|---|
3.50 | TU | P |
2.50 | TU | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 22, 1994 | FDA | PFIZER INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pulmonary embolism | 219.81 | 12.72 | 259 | 21057 | 108326 | 46556420 |
Hepatocellular injury | 124.22 | 12.72 | 105 | 21211 | 29417 | 46635329 |
Toxic epidermal necrolysis | 107.89 | 12.72 | 86 | 21230 | 22192 | 46642554 |
Drug ineffective | 103.38 | 12.72 | 95 | 21221 | 677743 | 45987003 |
Acute kidney injury | 96.91 | 12.72 | 281 | 21035 | 235574 | 46429172 |
General physical health deterioration | 95.04 | 12.72 | 181 | 21135 | 115588 | 46549158 |
Heparin-induced thrombocytopenia | 88.57 | 12.72 | 42 | 21274 | 4267 | 46660479 |
Thrombocytopenia | 88.42 | 12.72 | 185 | 21131 | 126396 | 46538350 |
Deep vein thrombosis | 74.60 | 12.72 | 132 | 21184 | 79641 | 46585105 |
Rheumatoid arthritis | 73.61 | 12.72 | 11 | 21305 | 240204 | 46424542 |
Neutropenic sepsis | 62.72 | 12.72 | 49 | 21267 | 12275 | 46652471 |
Cholestasis | 59.04 | 12.72 | 67 | 21249 | 26826 | 46637920 |
Arthralgia | 55.45 | 12.72 | 51 | 21265 | 364552 | 46300194 |
Product dose omission issue | 53.28 | 12.72 | 7 | 21309 | 168513 | 46496233 |
Blood creatine increased | 51.95 | 12.72 | 30 | 21286 | 4560 | 46660186 |
Anaemia | 47.15 | 12.72 | 236 | 21080 | 255543 | 46409203 |
Neutropenia | 45.23 | 12.72 | 156 | 21160 | 143048 | 46521698 |
Vessel puncture site bruise | 44.68 | 12.72 | 13 | 21303 | 328 | 46664418 |
Rash maculo-papular | 44.27 | 12.72 | 59 | 21257 | 27815 | 46636931 |
Malignant neoplasm progression | 44.22 | 12.72 | 94 | 21222 | 64832 | 46599914 |
Agranulocytosis | 43.23 | 12.72 | 52 | 21264 | 22133 | 46642613 |
Melaena | 42.91 | 12.72 | 58 | 21258 | 27714 | 46637032 |
Arteriovenous fistula occlusion | 40.72 | 12.72 | 12 | 21304 | 317 | 46664429 |
Venous pressure jugular decreased | 40.68 | 12.72 | 8 | 21308 | 32 | 46664714 |
Febrile neutropenia | 39.93 | 12.72 | 114 | 21202 | 94513 | 46570233 |
Blue toe syndrome | 39.82 | 12.72 | 12 | 21304 | 343 | 46664403 |
Ovarian hyperstimulation syndrome | 39.18 | 12.72 | 22 | 21294 | 3170 | 46661576 |
Pituitary tumour | 39.14 | 12.72 | 15 | 21301 | 900 | 46663846 |
Adrenal suppression | 38.57 | 12.72 | 15 | 21301 | 936 | 46663810 |
Drug intolerance | 38.18 | 12.72 | 10 | 21306 | 147039 | 46517707 |
Hypothalamo-pituitary disorder | 35.86 | 12.72 | 13 | 21303 | 667 | 46664079 |
Drug reaction with eosinophilia and systemic symptoms | 35.82 | 12.72 | 55 | 21261 | 29493 | 46635253 |
Thrombosis | 35.69 | 12.72 | 79 | 21237 | 55990 | 46608756 |
Gamma-glutamyltransferase increased | 35.59 | 12.72 | 57 | 21259 | 31683 | 46633063 |
Headache | 35.35 | 12.72 | 107 | 21209 | 478245 | 46186501 |
Haemoglobin decreased | 35.21 | 12.72 | 134 | 21182 | 128815 | 46535931 |
Drug hypersensitivity | 34.82 | 12.72 | 36 | 21280 | 243789 | 46420957 |
Perforation | 34.56 | 12.72 | 14 | 21302 | 973 | 46663773 |
Pancytopenia | 34.46 | 12.72 | 101 | 21215 | 84957 | 46579789 |
Blood loss anaemia | 33.05 | 12.72 | 29 | 21287 | 8528 | 46656218 |
Depression | 32.00 | 12.72 | 19 | 21297 | 170085 | 46494661 |
Abdominal wall haemorrhage | 30.59 | 12.72 | 8 | 21308 | 134 | 46664612 |
Haematoma | 30.09 | 12.72 | 53 | 21263 | 31819 | 46632927 |
Sinusitis | 29.78 | 12.72 | 11 | 21305 | 129757 | 46534989 |
Feeling abnormal | 29.73 | 12.72 | 10 | 21306 | 125050 | 46539696 |
Pneumothorax traumatic | 29.64 | 12.72 | 8 | 21308 | 152 | 46664594 |
Cerebral haemorrhage | 27.85 | 12.72 | 48 | 21268 | 28323 | 46636423 |
Abdominal wall haematoma | 27.83 | 12.72 | 17 | 21299 | 2864 | 46661882 |
Dermatitis exfoliative | 27.52 | 12.72 | 22 | 21294 | 5694 | 46659052 |
Blood creatinine increased | 27.46 | 12.72 | 87 | 21229 | 76316 | 46588430 |
Hyperkalaemia | 27.39 | 12.72 | 67 | 21249 | 50642 | 46614104 |
Jaundice | 27.28 | 12.72 | 48 | 21268 | 28797 | 46635949 |
Cardiomyopathy acute | 27.20 | 12.72 | 8 | 21308 | 210 | 46664536 |
Pyrexia | 26.94 | 12.72 | 260 | 21056 | 348542 | 46316204 |
Biliary sepsis | 26.77 | 12.72 | 10 | 21306 | 559 | 46664187 |
Gastric antral vascular ectasia | 26.55 | 12.72 | 10 | 21306 | 572 | 46664174 |
Catheter site thrombosis | 26.40 | 12.72 | 7 | 21309 | 124 | 46664622 |
Psychiatric decompensation | 26.35 | 12.72 | 12 | 21304 | 1111 | 46663635 |
Activated partial thromboplastin time prolonged | 25.91 | 12.72 | 23 | 21293 | 6866 | 46657880 |
Intra-abdominal haemorrhage | 25.76 | 12.72 | 15 | 21301 | 2315 | 46662431 |
Hyperthyroidism | 25.39 | 12.72 | 29 | 21287 | 11682 | 46653064 |
Bronchopulmonary dysplasia | 25.36 | 12.72 | 8 | 21308 | 267 | 46664479 |
Cardiac failure | 25.12 | 12.72 | 87 | 21229 | 79861 | 46584885 |
Haemorrhagic erosive gastritis | 25.00 | 12.72 | 8 | 21308 | 280 | 46664466 |
Bone marrow eosinophilic leukocyte count increased | 24.86 | 12.72 | 5 | 21311 | 23 | 46664723 |
Therapeutic product effect decreased | 24.77 | 12.72 | 4 | 21312 | 82597 | 46582149 |
Exposure during pregnancy | 24.40 | 12.72 | 106 | 21210 | 108106 | 46556640 |
Allergic hepatitis | 23.89 | 12.72 | 5 | 21311 | 29 | 46664717 |
Drug interaction | 23.52 | 12.72 | 166 | 21150 | 202928 | 46461818 |
Arthropathy | 23.47 | 12.72 | 5 | 21311 | 84695 | 46580051 |
Muscle haemorrhage | 23.30 | 12.72 | 16 | 21300 | 3288 | 46661458 |
Ascites | 22.66 | 12.72 | 51 | 21265 | 36533 | 46628213 |
Phlebitis | 22.43 | 12.72 | 20 | 21296 | 6006 | 46658740 |
Premature baby | 22.35 | 12.72 | 34 | 21282 | 18078 | 46646668 |
Gastrointestinal haemorrhage | 21.59 | 12.72 | 81 | 21235 | 77292 | 46587454 |
Femoral neck fracture | 20.93 | 12.72 | 22 | 21294 | 8081 | 46656665 |
Pleural effusion | 20.83 | 12.72 | 84 | 21232 | 82868 | 46581878 |
Abdominal discomfort | 20.79 | 12.72 | 23 | 21293 | 151142 | 46513604 |
Hepatitis cholestatic | 20.68 | 12.72 | 20 | 21296 | 6657 | 46658089 |
Cardiac failure congestive | 20.67 | 12.72 | 8 | 21308 | 91742 | 46573004 |
Pain | 20.37 | 12.72 | 131 | 21185 | 476817 | 46187929 |
Caesarean section | 20.25 | 12.72 | 31 | 21285 | 16572 | 46648174 |
Granulomatous liver disease | 19.93 | 12.72 | 9 | 21307 | 817 | 46663929 |
Neoplasm progression | 19.76 | 12.72 | 40 | 21276 | 26643 | 46638103 |
Renal tubular acidosis | 19.67 | 12.72 | 11 | 21305 | 1572 | 46663174 |
Intra-abdominal haematoma | 19.37 | 12.72 | 11 | 21305 | 1620 | 46663126 |
Cholestatic liver injury | 19.34 | 12.72 | 12 | 21304 | 2078 | 46662668 |
Foetal growth restriction | 19.09 | 12.72 | 19 | 21297 | 6548 | 46658198 |
Joint swelling | 19.00 | 12.72 | 29 | 21287 | 166044 | 46498702 |
Haematoma muscle | 18.92 | 12.72 | 8 | 21308 | 620 | 46664126 |
Retroperitoneal haemorrhage | 18.73 | 12.72 | 13 | 21303 | 2717 | 46662029 |
Diarrhoea haemorrhagic | 18.71 | 12.72 | 20 | 21296 | 7489 | 46657257 |
Sepsis | 18.65 | 12.72 | 116 | 21200 | 135898 | 46528848 |
Musculoskeletal stiffness | 18.34 | 12.72 | 11 | 21305 | 97982 | 46566764 |
Fatigue | 18.25 | 12.72 | 184 | 21132 | 608513 | 46056233 |
Limbal swelling | 18.11 | 12.72 | 4 | 21312 | 31 | 46664715 |
Electrolyte imbalance | 18.04 | 12.72 | 30 | 21286 | 17196 | 46647550 |
Anaemia folate deficiency | 17.77 | 12.72 | 6 | 21310 | 249 | 46664497 |
Multiple organ dysfunction syndrome | 17.77 | 12.72 | 58 | 21258 | 51652 | 46613094 |
Epistaxis | 17.67 | 12.72 | 67 | 21249 | 64238 | 46600508 |
Gastric ulcer | 17.67 | 12.72 | 34 | 21282 | 21829 | 46642917 |
Cerebral infarction | 17.26 | 12.72 | 35 | 21281 | 23331 | 46641415 |
Alanine aminotransferase increased | 17.22 | 12.72 | 83 | 21233 | 88368 | 46576378 |
Lordosis | 17.04 | 12.72 | 6 | 21310 | 283 | 46664463 |
Protein C decreased | 16.85 | 12.72 | 4 | 21312 | 44 | 46664702 |
Respiratory disorder | 16.84 | 12.72 | 38 | 21278 | 27262 | 46637484 |
Treatment failure | 16.66 | 12.72 | 11 | 21305 | 93076 | 46571670 |
Haemolysis | 16.64 | 12.72 | 17 | 21299 | 6042 | 46658704 |
Acute generalised exanthematous pustulosis | 16.63 | 12.72 | 21 | 21295 | 9384 | 46655362 |
Faecaloma | 16.47 | 12.72 | 19 | 21297 | 7733 | 46657013 |
Pneumobilia | 16.20 | 12.72 | 5 | 21311 | 155 | 46664591 |
Asthma | 16.14 | 12.72 | 11 | 21305 | 91531 | 46573215 |
Maternal drugs affecting foetus | 16.10 | 12.72 | 16 | 21300 | 5502 | 46659244 |
Gastrointestinal tract adenoma | 16.08 | 12.72 | 6 | 21310 | 334 | 46664412 |
Varices oesophageal | 16.08 | 12.72 | 12 | 21304 | 2807 | 46661939 |
Constipation | 16.07 | 12.72 | 135 | 21181 | 173962 | 46490784 |
Blood alkaline phosphatase increased | 15.99 | 12.72 | 47 | 21269 | 39562 | 46625184 |
Visual acuity reduced transiently | 15.96 | 12.72 | 5 | 21311 | 163 | 46664583 |
Protein S decreased | 15.96 | 12.72 | 4 | 21312 | 56 | 46664690 |
Hyperlipasaemia | 15.92 | 12.72 | 7 | 21309 | 597 | 46664149 |
Toxicity to various agents | 15.84 | 12.72 | 47 | 21269 | 211719 | 46453027 |
Infantile haemangioma | 15.83 | 12.72 | 4 | 21312 | 58 | 46664688 |
Therapeutic product effect incomplete | 15.74 | 12.72 | 8 | 21308 | 78145 | 46586601 |
Intracranial pressure increased | 15.70 | 12.72 | 14 | 21302 | 4206 | 46660540 |
Cerebellar haematoma | 15.53 | 12.72 | 6 | 21310 | 368 | 46664378 |
Mucosal inflammation | 15.50 | 12.72 | 46 | 21270 | 38930 | 46625816 |
Chemotherapeutic drug level increased | 15.49 | 12.72 | 5 | 21311 | 180 | 46664566 |
Needle issue | 15.42 | 12.72 | 16 | 21300 | 5788 | 46658958 |
Acidosis | 15.26 | 12.72 | 22 | 21294 | 11152 | 46653594 |
Gait disturbance | 15.10 | 12.72 | 27 | 21289 | 145236 | 46519510 |
Thrombophlebitis | 15.09 | 12.72 | 14 | 21302 | 4423 | 46660323 |
Cardiac hypertrophy | 14.95 | 12.72 | 8 | 21308 | 1049 | 46663697 |
Cholecystitis | 14.89 | 12.72 | 25 | 21291 | 14441 | 46650305 |
Persecutory delusion | 14.85 | 12.72 | 11 | 21305 | 2544 | 46662202 |
International normalised ratio increased | 14.70 | 12.72 | 51 | 21265 | 46832 | 46617914 |
Haemoptysis | 14.56 | 12.72 | 35 | 21281 | 26154 | 46638592 |
Embolism | 14.34 | 12.72 | 17 | 21299 | 7121 | 46657625 |
Subcutaneous haematoma | 14.33 | 12.72 | 9 | 21307 | 1592 | 46663154 |
Abdominal pain | 14.20 | 12.72 | 164 | 21152 | 229867 | 46434879 |
Hyperhidrosis | 14.12 | 12.72 | 12 | 21304 | 89296 | 46575450 |
Vena cava thrombosis | 14.07 | 12.72 | 10 | 21306 | 2169 | 46662577 |
Chondrodystrophy | 14.06 | 12.72 | 4 | 21312 | 93 | 46664653 |
Haemangioma congenital | 13.96 | 12.72 | 6 | 21310 | 484 | 46664262 |
Stevens-Johnson syndrome | 13.89 | 12.72 | 32 | 21284 | 23265 | 46641481 |
Foetal growth abnormality | 13.85 | 12.72 | 3 | 21313 | 21 | 46664725 |
Bone marrow oedema | 13.71 | 12.72 | 7 | 21309 | 834 | 46663912 |
Vascular occlusion | 13.61 | 12.72 | 7 | 21309 | 846 | 46663900 |
Engraftment syndrome | 13.37 | 12.72 | 5 | 21311 | 280 | 46664466 |
Red cell distribution width increased | 13.31 | 12.72 | 17 | 21299 | 7687 | 46657059 |
Eosinophilia | 13.27 | 12.72 | 28 | 21288 | 19189 | 46645557 |
Leukopenia | 13.20 | 12.72 | 64 | 21252 | 68279 | 46596467 |
Post procedural haematoma | 13.12 | 12.72 | 8 | 21308 | 1343 | 46663403 |
Injection site erythema | 13.04 | 12.72 | 9 | 21307 | 74418 | 46590328 |
Injection site pain | 12.95 | 12.72 | 18 | 21298 | 107134 | 46557612 |
Alopecia | 12.91 | 12.72 | 35 | 21281 | 162379 | 46502367 |
Application site haemorrhage | 12.88 | 12.72 | 7 | 21309 | 947 | 46663799 |
Loss of personal independence in daily activities | 12.86 | 12.72 | 5 | 21311 | 57178 | 46607568 |
Alveolitis | 12.80 | 12.72 | 10 | 21306 | 2503 | 46662243 |
Erythema | 12.77 | 12.72 | 110 | 21206 | 142710 | 46522036 |
Osteochondrosis | 12.77 | 12.72 | 7 | 21309 | 963 | 46663783 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pulmonary embolism | 116.43 | 12.88 | 189 | 18493 | 77946 | 29855850 |
Hepatocellular injury | 85.62 | 12.88 | 92 | 18590 | 25379 | 29908417 |
Drug ineffective | 75.85 | 12.88 | 61 | 18621 | 340326 | 29593470 |
General physical health deterioration | 72.52 | 12.88 | 179 | 18503 | 99765 | 29834031 |
Thrombocytopenia | 64.66 | 12.88 | 210 | 18472 | 136834 | 29796962 |
Acute kidney injury | 62.88 | 12.88 | 336 | 18346 | 273506 | 29660290 |
Heparin-induced thrombocytopenia | 57.59 | 12.88 | 38 | 18644 | 5345 | 29928451 |
Lymph node calcification | 51.67 | 12.88 | 14 | 18668 | 194 | 29933602 |
Appendicolith | 51.63 | 12.88 | 20 | 18662 | 899 | 29932897 |
Toxic epidermal necrolysis | 48.69 | 12.88 | 58 | 18624 | 17882 | 29915914 |
Neutropenia | 47.66 | 12.88 | 182 | 18500 | 128358 | 29805438 |
Toxicity to various agents | 37.79 | 12.88 | 33 | 18649 | 177150 | 29756646 |
Pulmonary sarcoidosis | 37.41 | 12.88 | 14 | 18668 | 572 | 29933224 |
Deep vein thrombosis | 37.27 | 12.88 | 102 | 18580 | 60399 | 29873397 |
Drug abuse | 37.05 | 12.88 | 4 | 18678 | 82068 | 29851728 |
Sepsis | 36.47 | 12.88 | 184 | 18498 | 146211 | 29787585 |
Aplasia | 34.92 | 12.88 | 25 | 18657 | 4012 | 29929784 |
Haemorrhage | 31.74 | 12.88 | 81 | 18601 | 45998 | 29887798 |
Mucosal inflammation | 31.52 | 12.88 | 63 | 18619 | 30431 | 29903365 |
Bronchial disorder | 31.39 | 12.88 | 14 | 18668 | 900 | 29932896 |
Suspected product quality issue | 30.87 | 12.88 | 9 | 18673 | 165 | 29933631 |
Muscle haemorrhage | 29.91 | 12.88 | 22 | 18660 | 3681 | 29930115 |
Hepatic haematoma | 28.77 | 12.88 | 11 | 18671 | 477 | 29933319 |
Peritoneal haematoma | 28.59 | 12.88 | 7 | 18675 | 63 | 29933733 |
Haematemesis | 28.13 | 12.88 | 55 | 18627 | 26148 | 29907648 |
Bronchial obstruction | 27.79 | 12.88 | 15 | 18667 | 1461 | 29932335 |
Pancytopenia | 27.13 | 12.88 | 115 | 18567 | 84937 | 29848859 |
Chondrocalcinosis | 27.01 | 12.88 | 9 | 18673 | 260 | 29933536 |
Floppy infant | 26.61 | 12.88 | 7 | 18675 | 86 | 29933710 |
Death | 26.42 | 12.88 | 124 | 18558 | 357159 | 29576637 |
Septic shock | 25.98 | 12.88 | 93 | 18589 | 63514 | 29870282 |
Hyperkalaemia | 25.68 | 12.88 | 95 | 18587 | 65915 | 29867881 |
Compartment syndrome | 25.01 | 12.88 | 17 | 18665 | 2510 | 29931286 |
Genitalia external ambiguous | 23.92 | 12.88 | 8 | 18674 | 234 | 29933562 |
Lung cancer metastatic | 22.66 | 12.88 | 16 | 18666 | 2512 | 29931284 |
Febrile neutropenia | 22.38 | 12.88 | 128 | 18554 | 106565 | 29827231 |
Rash maculo-papular | 22.18 | 12.88 | 49 | 18633 | 25369 | 29908427 |
Congenital bladder anomaly | 22.08 | 12.88 | 8 | 18674 | 298 | 29933498 |
Haematoma | 21.84 | 12.88 | 47 | 18635 | 23906 | 29909890 |
Abdominal pain | 21.78 | 12.88 | 152 | 18530 | 135502 | 29798294 |
Mucosal disorder | 21.62 | 12.88 | 13 | 18669 | 1554 | 29932242 |
Klebsiella infection | 21.60 | 12.88 | 24 | 18658 | 6863 | 29926933 |
Embolism | 21.25 | 12.88 | 24 | 18658 | 6985 | 29926811 |
Respiratory tract infection | 21.01 | 12.88 | 36 | 18646 | 15470 | 29918326 |
Product dose omission issue | 20.83 | 12.88 | 16 | 18666 | 91615 | 29842181 |
Cholestasis | 20.54 | 12.88 | 47 | 18635 | 24903 | 29908893 |
Thrombocytosis | 20.46 | 12.88 | 17 | 18665 | 3396 | 29930400 |
Foetal hypokinesia | 20.45 | 12.88 | 8 | 18674 | 369 | 29933427 |
Haemorrhagic disorder | 20.37 | 12.88 | 9 | 18673 | 566 | 29933230 |
Malignant neoplasm progression | 20.21 | 12.88 | 94 | 18588 | 72193 | 29861603 |
Full blood count abnormal | 20.21 | 12.88 | 11 | 18671 | 1089 | 29932707 |
Hypokalaemia | 20.16 | 12.88 | 73 | 18609 | 50119 | 29883677 |
Cardiac failure congestive | 20.14 | 12.88 | 14 | 18668 | 84393 | 29849403 |
Coagulation factor VII level decreased | 20.09 | 12.88 | 6 | 18676 | 120 | 29933676 |
Product communication issue | 19.95 | 12.88 | 5 | 18677 | 50 | 29933746 |
Respiratory disorder neonatal | 19.42 | 12.88 | 11 | 18671 | 1177 | 29932619 |
Neonatal respiratory depression | 19.38 | 12.88 | 8 | 18674 | 425 | 29933371 |
Pulmonary artery thrombosis | 19.18 | 12.88 | 9 | 18673 | 651 | 29933145 |
Prothrombin time shortened | 19.16 | 12.88 | 12 | 18670 | 1543 | 29932253 |
Depression | 19.06 | 12.88 | 17 | 18665 | 90420 | 29843376 |
Haemolytic anaemia | 18.79 | 12.88 | 27 | 18655 | 9983 | 29923813 |
Dizziness | 18.60 | 12.88 | 61 | 18621 | 194848 | 29738948 |
Appendicitis | 18.56 | 12.88 | 21 | 18661 | 6123 | 29927673 |
Reading disorder | 18.39 | 12.88 | 7 | 18675 | 300 | 29933496 |
Jaundice cholestatic | 18.09 | 12.88 | 18 | 18664 | 4533 | 29929263 |
Hypertrophic osteoarthropathy | 17.50 | 12.88 | 5 | 18677 | 85 | 29933711 |
Butterfly rash | 17.08 | 12.88 | 5 | 18677 | 93 | 29933703 |
Wrong strength | 16.60 | 12.88 | 5 | 18677 | 103 | 29933693 |
Eosinophil percentage decreased | 16.42 | 12.88 | 5 | 18677 | 107 | 29933689 |
Cardiac flutter | 16.24 | 12.88 | 11 | 18671 | 1615 | 29932181 |
Miosis | 16.12 | 12.88 | 22 | 18660 | 7754 | 29926042 |
Hepatitis cholestatic | 15.91 | 12.88 | 22 | 18660 | 7850 | 29925946 |
Drug hypersensitivity | 15.52 | 12.88 | 12 | 18670 | 68507 | 29865289 |
Therapeutic product effect prolonged | 15.27 | 12.88 | 6 | 18676 | 280 | 29933516 |
Cardiogenic shock | 15.27 | 12.88 | 33 | 18649 | 16828 | 29916968 |
Abdominal sepsis | 15.19 | 12.88 | 9 | 18673 | 1048 | 29932748 |
Leukopenia | 14.94 | 12.88 | 72 | 18610 | 56087 | 29877709 |
Large intestine perforation | 14.90 | 12.88 | 21 | 18661 | 7630 | 29926166 |
Insomnia | 14.84 | 12.88 | 22 | 18660 | 93314 | 29840482 |
Gamma-glutamyltransferase increased | 14.71 | 12.88 | 46 | 18636 | 29304 | 29904492 |
Lung disorder | 14.57 | 12.88 | 48 | 18634 | 31421 | 29902375 |
Lymphopenia | 14.57 | 12.88 | 28 | 18654 | 13135 | 29920661 |
Agranulocytosis | 14.51 | 12.88 | 38 | 18644 | 21904 | 29911892 |
Anxiety | 14.47 | 12.88 | 21 | 18661 | 89850 | 29843946 |
Engraftment syndrome | 14.40 | 12.88 | 8 | 18674 | 825 | 29932971 |
Portal vein thrombosis | 14.33 | 12.88 | 14 | 18668 | 3450 | 29930346 |
Cerebral haemorrhage | 14.20 | 12.88 | 49 | 18633 | 32838 | 29900958 |
Pyrexia | 14.19 | 12.88 | 260 | 18422 | 294229 | 29639567 |
Myositis | 13.93 | 12.88 | 24 | 18658 | 10353 | 29923443 |
Metastatic malignant melanoma | 13.86 | 12.88 | 11 | 18671 | 2059 | 29931737 |
Penile necrosis | 13.84 | 12.88 | 4 | 18678 | 71 | 29933725 |
Neoplasm progression | 13.79 | 12.88 | 33 | 18649 | 17990 | 29915806 |
Soft tissue sarcoma | 13.69 | 12.88 | 4 | 18678 | 74 | 29933722 |
Phlebitis | 13.32 | 12.88 | 14 | 18668 | 3761 | 29930035 |
Bicytopenia | 13.18 | 12.88 | 10 | 18672 | 1752 | 29932044 |
IIIrd nerve disorder | 13.08 | 12.88 | 4 | 18678 | 87 | 29933709 |
Gastrointestinal stoma output increased | 13.04 | 12.88 | 3 | 18679 | 20 | 29933776 |
Foetal exposure during delivery | 13.04 | 12.88 | 4 | 18678 | 88 | 29933708 |
Blood pressure diastolic increased | 13.03 | 12.88 | 12 | 18670 | 2746 | 29931050 |
Bladder tamponade | 12.90 | 12.88 | 6 | 18676 | 425 | 29933371 |
Source | Code | Description |
---|---|---|
ATC | B01AB10 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group |
ATC | B01AB12 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Heparin group |
FDA CS | M0010191 | Heparin, Low-Molecular-Weight |
FDA EPC | N0000175586 | Low Molecular Weight Heparin |
MeSH PA | D000925 | Anticoagulants |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D005343 | Fibrinolytic Agents |
MeSH PA | D006401 | Hematologic Agents |
CHEBI has role | CHEBI:50249 | anticoagulante |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pulmonary embolism | indication | 59282003 | DOID:9477 |
Deep venous thrombosis | indication | 128053003 |
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
10,000IU/0.4ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | May 1, 2007 | DISCN | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
10,000IU/ML (10,000IU/ML) | FRAGMIN | PFIZER | N020287 | Jan. 30, 1998 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
12,500IU/0.5ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | May 1, 2007 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
15,000IU/0.6ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | May 1, 2007 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
18,000IU/0.72ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | May 1, 2007 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
2,500IU/0.2ML (12,500IU/ML) | FRAGMIN | PFIZER | N020287 | Dec. 22, 1994 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
5,000IU/0.2ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | March 18, 1996 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
7,500 IU/0.75ML | FRAGMIN | PFIZER | N020287 | April 4, 2002 | DISCN | INJECTABLE | INJECTION | May 16, 2022 | NEW PATIENT POPULATION |
7,500IU/0.3ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | April 4, 2002 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
95,000IU/3.8ML (25,000IU/ML) | FRAGMIN | PFIZER | N020287 | April 4, 2002 | RX | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
95,000IU/9.5ML (10,000IU/ML) | FRAGMIN | PFIZER | N020287 | April 4, 2002 | DISCN | INJECTABLE | SUBCUTANEOUS | May 16, 2022 | NEW PATIENT POPULATION |
None
ID | Source |
---|---|
N3927D01PB | UNII |
9005-49-6 | SECONDARY_CAS_RN |
4020894 | VANDF |
4021054 | VANDF |
4021237 | VANDF |
4024199 | VANDF |
C0297268 | UMLSCUI |
CHEBI:28304 | CHEBI |
CHEMBL1201448 | ChEMBL_ID |
CHEMBL3707365 | ChEMBL_ID |
CHEMBL2108806 | ChEMBL_ID |
CHEMBL1201460 | ChEMBL_ID |
DB09258 | DRUGBANK_ID |
CHEMBL1201414 | ChEMBL_ID |
6985 | INN_ID |
7501 | INN_ID |
D017985 | MESH_DESCRIPTOR_UI |
D000078222 | MESH_DESCRIPTOR_UI |
C093450 | MESH_SUPPLEMENTAL_RECORD_UI |
C411345 | MESH_SUPPLEMENTAL_RECORD_UI |
772 | PUBCHEM_CID |
5688 | INN_ID |
6764 | INN_ID |
DB06822 | DRUGBANK_ID |
6846 | IUPHAR_LIGAND_ID |
104466 | RXNORM |
15471 | MMSL |
4531 | MMSL |
d04659 | MMSL |
005078 | NDDF |
007911 | NDDF |
008338 | NDDF |
108987000 | SNOMEDCT_US |
108990006 | SNOMEDCT_US |
350469004 | SNOMEDCT_US |
395908006 | SNOMEDCT_US |
410964003 | SNOMEDCT_US |
410965002 | SNOMEDCT_US |
410967005 | SNOMEDCT_US |
412608008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0195 | INJECTION | 2500 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0196 | INJECTION | 5000 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0206 | INJECTION | 7500 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0217 | INJECTION | 10000 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0220 | INJECTION | 12500 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0223 | INJECTION | 15000 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0228 | INJECTION | 18000 [iU] | SUBCUTANEOUS | NDA | 28 sections |
Fragmin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0232 | INJECTION | 25000 [iU] | SUBCUTANEOUS | NDA | 28 sections |